Le Lézard
Classified in: Health
Subjects: PER, MAT

Dr. Honig Joins Legacy as Strategic Advisor, Bringing Expertise in Male Reproductive Health and Urology


Distinguished Professor and Leader in Male Fertility Care to Guide Innovation at Legacy, the Leading Sperm Freezing & Testing Company

NEW YORK, March 5, 2024 /PRNewswire/ -- Legacy, the leading provider of at-home sperm testing and freezing solutions in the United States, proudly announces the appointment of Dr. Honig, a distinguished Professor of Urology and Division Chief of Sexual and Reproductive Medicine at Yale University School of Medicine, as a Strategic Advisor.

Dr. Honig's extensive expertise in male reproductive health and urology will significantly enhance Legacy's commitment to innovation in the field of male fertility care. With a remarkable background in academia and clinical practice, Dr. Honig brings a wealth of experience to his new role at Legacy.

As the past President of the Society for the Study of Male Reproduction (SSMR) and the Society for Male Reproduction/Urology (SMRU), Dr. Honig has played a pivotal role in advancing research and understanding in male reproductive medicine. Additionally, his contributions as Chairman of the Sexual and Reproductive Committee of the Urology Care Foundation and membership on various urology guidelines committees underscore his leadership and dedication to improving patient care and outcomes.

"I am thrilled to join Legacy as a Strategic Advisor," said Dr. Honig. "The company's commitment to advancing male fertility care aligns with my passion for enhancing access to comprehensive reproductive health services. I am eager to contribute to Legacy's innovative approach and help shape the future of male fertility care."

In his role as a Strategic Advisor, Dr. Honig will provide valuable guidance and strategic vision to further propel Legacy's mission of revolutionizing male fertility care. His expertise will be instrumental in shaping the company's roadmap for continued innovation and expansion in the field.

"We are delighted to welcome Dr. Honig to the Legacy team," said Khaled Kteily, CEO and Founder of Legacy. "His unparalleled expertise and dedication to advancing male reproductive health will be invaluable as we continue to push the boundaries of at-home sperm testing and freezing solutions."

Legacy, founded in 2018 at Harvard University, has been at the forefront of providing accessible at-home sperm testing and freezing services. With partnerships across leading health plans, fertility benefits providers, and US military programs, Legacy has successfully served thousands of patients, delivering high-quality fertility solutions with convenience and accessibility.

To learn more about Legacy and its innovative fertility solutions, please visit Legacy's Website.

ABOUT GIVE LEGACY, INC.

Legacy is the largest male fertility clinic in North America, offering customers the ability to test their sperm from the comfort of their home and preserve their fertility for future use. Legacy's fertility solutions are trusted by leading health plans, employee benefits providers, and the US Department of Veterans Affairs to reduce costs and drive better outcomes by prioritizing male-factor fertility. Founded at Harvard University in 2018, Legacy pioneered direct access to male fertility information, allowing customers to test for semen analysis, DNA fragmentation analysis, STI testing, and cryopreserve their sperm without leaving their homes. Legacy is currently available across the United States and is the only digital fertility clinic to offer both post-thaw analysis and multi-site storage for maximum viability and security of all samples. To learn more about Legacy, visit us at givelegacy.com.

SOURCE Legacy


These press releases may also interest you

at 01:30
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the...

at 01:00
Management Report1 Q1 2024 highlights Strong performance in Perfumery & Beauty on good demand developmentGood performance in Taste, Texture & Health underpinned by market recoveryHealth, Nutrition & Care was soft, with improving momentum by end of...

at 00:01
Today, the Conference on Jewish Material Claims Against Germany (Claims Conference) launched a new digital campaign, #CancelHate. The campaign features Holocaust survivors reading Holocaust denial posts from across social media platforms. Each post...

at 00:00
With over four decades of nursing experience under her belt, Sherry Shaffer Ratajczak has witnessed firsthand the dedication of her colleagues in patient care. Yet, she observed a common misunderstanding: many are unaware of the extensive knowledge...

1 mai 2024
Today, a decision was issued by the Court of Appeals Division I in the State of Washington in Erickson v. Monsanto, ruling in Monsanto's favor on multiple grounds. This decision reverses the initial verdict of $185 million in its entirety and...

1 mai 2024
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc.  today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a...



News published on and distributed by: